Video

Dr. Rule on Long-Term Follow-Up of Ibrutinib Monotherapy in Relapsed/Refractory MCL

Author(s):

Simon Rule, MD

Simon Rule, MD, professor of hematology, University of Plymouth, discusses long-term follow-up data from a pooled analysis of ibrutinib (Imbruvica) monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL).

Simon Rule, MD, professor of hematology, University of Plymouth, discusses long-term follow-up data from a pooled analysis of ibrutinib (Imbruvica) monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL).

<<< View more from 2019 ASH Annual Meeting

Related Videos
Elizabeth A. Brem, MD
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Sandip P. Patel, MD
Pooja Phull, MD
Bhavana "Tina" Bhatnagar, DO
Ashkan Emadi, MD, PhD
Alexis LeVee, MD
Martin Dreyling, MD
Tom van Meerten, MD, PhD, hematologist, Department of Hematology, University Medical Center Groningen
Related Content
Tom van Meerten, MD, PhD, hematologist, Department of Hematology, University Medical Center Groningen
January 6th 2025

ZUMA-2 Data Support Earlier-Line Role for Brexu-Cel in High-Risk R/R MCL Subgroups

Lori A. Leslie, MD
February 27th 2023

FDA Approval Insights: Pirtobrutinib in MCL

Mantle cell lymphoma | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 18th 2024

Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL

Joshua Brody, MD
December 8th 2022

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

Myelofibrosis | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 18th 2024

Acalabrutinib Regimen Demonstrates Efficacy in De Novo Mantle Cell Lymphoma

Mantle Cell Lymphoma | stock.adobe.com
December 17th 2024

Glofitamab Produces Durable Remissions in R/R Mantle Cell Lymphoma